These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7750123)

  • 1. Linear epitopes of the replication-activator protein of Epstein-Barr virus recognised by specific serum IgG in nasopharyngeal carcinoma.
    Cheng HM; Foong YT; AbuSamah AJ; Dillner J; Sam CK; Prasad U
    Cancer Immunol Immunother; 1995 Apr; 40(4):251-6. PubMed ID: 7750123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
    Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
    J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The disease associations of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes.
    Tedeschi R; Foong YT; Cheng HM; dePaoli P; Lehtinen T; Elfborg T; Dillner J
    J Gen Virol; 1995 Jun; 76 ( Pt 6)():1393-400. PubMed ID: 7540196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high incidence of serum IgG antibodies to the Epstein-Barr virus replication activator protein in nasopharyngeal carcinoma.
    Mathew A; Cheng HM; Sam CK; Joab I; Prasad U; Cochet C
    Cancer Immunol Immunother; 1994 Jan; 38(1):68-70. PubMed ID: 8299121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma.
    Yip TT; Ngan RK; Lau WH; Poon YF; Joab I; Cochet C; Cheng AK
    Cancer; 1994 Nov; 74(9):2414-24. PubMed ID: 7922994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of IgA against Epstein-Barr virus BZLF-1 replication activator (ZEBRA) in sera of nasopharyngeal carcinoma patients with a recombinant ZEBRA protein.
    Shu CH; Tu TY; Lin LS; Ro LH; Lo MS; Huang CH; Chen KY; Liu WT
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jun; 62(6):350-5. PubMed ID: 10389292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma.
    Dardari R; Khyatti M; Benider A; Jouhadi H; Kahlain A; Cochet C; Mansouri A; El Gueddari B; Benslimane A; Joab I
    Int J Cancer; 2000 Apr; 86(1):71-5. PubMed ID: 10728597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors.
    Cheng HM; Foong YT; Sam CK; Prasad U; Dillner J
    J Clin Microbiol; 1991 Oct; 29(10):2180-6. PubMed ID: 1719023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigens p54 and p138.
    Dardari R; Hinderer W; Lang D; Benider A; El Gueddari B; Joab I; Benslimane A; Khyatti M
    J Clin Microbiol; 2001 Sep; 39(9):3164-70. PubMed ID: 11526145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for nasopharyngeal carcinoma with an ELISA using the Epstein-Barr virus nuclear antigen, EBNA 1: a complementary test to the IgA/VCA immunofluorescence assay.
    Cheng HM; Foong YT; Mathew A; Sam CK; Dillner J; Prasad U
    J Virol Methods; 1993 Apr; 42(1):45-51. PubMed ID: 7686558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody response to Epstein-Barr virus Rta protein in patients with nasopharyngeal carcinoma: a new serologic parameter for diagnosis.
    Feng P; Chan SH; Soo MY; Liu D; Guan M; Ren EC; Hu H
    Cancer; 2001 Oct; 92(7):1872-80. PubMed ID: 11745260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of anti-Epstein-Barr-virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma.
    Joab I; Nicolas JC; Schwaab G; de-Thé G; Clausse B; Perricaudet M; Zeng Y
    Int J Cancer; 1991 Jul; 48(5):647-9. PubMed ID: 1649137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma.
    Chan KH; Gu YL; Ng F; Ng PS; Seto WH; Sham JS; Chua D; Wei W; Chen YL; Luk W; Zong YS; Ng MH
    Int J Cancer; 2003 Jul; 105(5):706-9. PubMed ID: 12740922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects.
    Fachiroh J; Schouten T; Hariwiyanto B; Paramita DK; Harijadi A; Haryana SM; Ng MH; Middeldorp JM
    J Infect Dis; 2004 Jul; 190(1):53-62. PubMed ID: 15195243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme-linked immunosorbent assay for antibodies to ZEBRA, an Epstein-Barr trans-activator.
    Maréchal V; Meyohas MC; Joab I; Gaha S; Giot JF; Sergeant A; Nicolas JC
    Res Virol; 1993; 144(5):397-404. PubMed ID: 8284517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma.
    Paramita DK; Fachiroh J; Artama WT; van Benthem E; Haryana SM; Middeldorp JM
    J Med Virol; 2007 Nov; 79(11):1710-21. PubMed ID: 17854043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
    Xia C; Zhu K; Zheng G
    Int J Clin Exp Pathol; 2015; 8(12):16104-10. PubMed ID: 26884888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rta-IgG as a biomarker for diagnosis and post treatment prognostic of nasopharyngeal carcinoma.
    Xu XF; Lu RQ; Xiao R; Zhou L; Zhao XM; Hu XC; Gao X; Guo L
    Cancer Biomark; 2016; 16(3):467-76. PubMed ID: 27062704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of epstein-barr virus antigenic sites on the carboxyl terminal end of ribonucleotide reductase against nasopharyngeal carcinoma serum antibodies using an immunoabsorption method.
    Gan YY; Hu R; Chai D; Tan TT; Gan YH; Chan SH; Tsao SY; Gan LH
    J Med Virol; 1999 Nov; 59(3):385-96. PubMed ID: 10502273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.